211 related articles for article (PubMed ID: 32844043)
1. Hepatobiliary manifestations in children with inflammatory bowel disease: A single-center experience in a low/middle income country.
El-Shabrawi MH; Tarek S; Abou-Zekri M; Meshaal S; Enayet A; Mogahed EA
World J Gastrointest Pharmacol Ther; 2020 Aug; 11(3):48-58. PubMed ID: 32844043
[TBL] [Abstract][Full Text] [Related]
2. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.
Mazza S; Soro S; Verga MC; Elvo B; Ferretti F; Cereatti F; Drago A; Grassia R
World J Hepatol; 2021 Dec; 13(12):1828-1849. PubMed ID: 35069993
[TBL] [Abstract][Full Text] [Related]
3. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.
Rojas-Feria M; Castro M; Suárez E; Ampuero J; Romero-Gómez M
World J Gastroenterol; 2013 Nov; 19(42):7327-40. PubMed ID: 24259964
[TBL] [Abstract][Full Text] [Related]
4. Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients.
Silva J; Brito BS; Silva INN; Nóbrega VG; da Silva MCSM; Gomes HDN; Fortes FM; Pimentel AM; Mota J; Almeida N; Surlo VC; Lyra A; Rocha R; Santana GO
Biomed Res Int; 2019; 2019():7604939. PubMed ID: 30834274
[TBL] [Abstract][Full Text] [Related]
5. Liver Pathology in Children with Diagnosed Inflammatory Bowel Disease-A Single Center Experience.
Daniluk U; Kwiatek-Sredzinska K; Jakimiec P; Daniluk J; Czajkowska A; Lebensztejn DM
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830641
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Clinical Course of Primary Sclerosing Cholangitis in Paediatric Population-Single Center Study.
Wiecek S; Wojtyniak A; Pindur B; Machnikowska-Sokołowska M; Gruszczyńska K; Grzybowska-Chlebowczyk U
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34199130
[No Abstract] [Full Text] [Related]
7. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients?
Bayraktar Y; Arslan S; Saglam F; Uzunalimoglu B; Kayhan B
Hepatogastroenterology; 1998; 45(24):2064-72. PubMed ID: 9951867
[TBL] [Abstract][Full Text] [Related]
8. Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
Fevery J; Van Steenbergen W; Van Pelt J; Laleman W; Hoffman I; Geboes K; Vermeire S; Nevens F
Aliment Pharmacol Ther; 2016 Mar; 43(5):612-20. PubMed ID: 26748470
[TBL] [Abstract][Full Text] [Related]
9. Colitis-associated sclerosing cholangitis in children: a single centre experience.
Noble-Jamieson G; Heuschkel RB; Torrente F; Hadzic N; Zilbauer M
J Crohns Colitis; 2013 Nov; 7(10):e414-8. PubMed ID: 23485432
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.
Singh A; Midha V; Narang V; Kedia S; Mahajan R; Dhoble P; Kahlon BK; Dhaliwal AS; Tripathi A; Kalra S; Jain NP; Bansal N; Banerjee R; Desai D; Dutta U; Ahuja V; Sood A
Intest Res; 2023 Oct; 21(4):452-459. PubMed ID: 36453008
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease.
Heikius B; Niemelä S; Lehtola J; Karttunen T; Lähde S
Scand J Gastroenterol; 1997 Feb; 32(2):153-61. PubMed ID: 9051876
[TBL] [Abstract][Full Text] [Related]
12. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries.
Dalzell AM; Ba'Ath ME
Paediatr Int Child Health; 2019 Feb; 39(1):48-58. PubMed ID: 30900526
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study.
Fousekis FS; Katsanos KH; Theopistos VI; Baltayiannis G; Kosmidou M; Glantzounis G; Christou L; Tsianos EV; Christodoulou DK
BMC Gastroenterol; 2019 Apr; 19(1):48. PubMed ID: 30943899
[TBL] [Abstract][Full Text] [Related]
14. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.
Fousekis FS; Theopistos VI; Katsanos KH; Tsianos EV; Christodoulou DK
Gastroenterology Res; 2018 Apr; 11(2):83-94. PubMed ID: 29707074
[TBL] [Abstract][Full Text] [Related]
15. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.
Navaneethan U; Shen B
Inflamm Bowel Dis; 2010 Sep; 16(9):1598-619. PubMed ID: 20198712
[TBL] [Abstract][Full Text] [Related]
16. Hepatobiliary manifestations in patients with ulcerative colitis: a retrospective analysis.
Stratmann K; Aydolmus S; Gu W; Heling D; Spengler U; Terjung B; Strassburg CP; Vollenberg R; Blumenstein I; Trebicka J
Front Med (Lausanne); 2023; 10():1273797. PubMed ID: 38249970
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease.
Gizard E; Ford AC; Bronowicki JP; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2014 Jul; 40(1):3-15. PubMed ID: 24815622
[TBL] [Abstract][Full Text] [Related]
18. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.
de Vries AB; Janse M; Blokzijl H; Weersma RK
World J Gastroenterol; 2015 Feb; 21(6):1956-71. PubMed ID: 25684965
[TBL] [Abstract][Full Text] [Related]
19. Liver biopsy in inflammatory bowel disease patients with sustained abnormal liver function tests: a retrospective single-center study.
Dias E; Andrade P; Lopes S; Gonçalves R; Cardoso P; Gaspar R; Cardoso H; Lopes J; Carneiro F; Macedo G
Ann Gastroenterol; 2023; 36(1):54-60. PubMed ID: 36593810
[TBL] [Abstract][Full Text] [Related]
20. Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome.
Hensel KO; Kyrana E; Hadzic N; Mann J; Mieli-Vergani G; Gasparetto M; Heuschkel R; Noble-Jamieson G; Samyn M
J Pediatr; 2021 Nov; 238():50-56.e3. PubMed ID: 34303727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
